

**APC anti-human CD261 (DR4, TRAIL-R1)**

**Catalog # / Size:** 2136035 / 25 tests  
2136040 / 100 tests

**Clone:** DJR1

**Isotype:** Mouse IgG1,  $\kappa$


**Immunogen:** Extracellular domain of DR4-human IgG1 Fc fusion protein

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** Lot-specific



Human DR4 transfected cells stained with DJR1 APC

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application References:**

1. Uno K, *et al.* 2003. *Blood* 101:3658.
2. Sato K, *et al.* 2005. *J. Immunol.* 174:4025.
3. Lundqvist A, *et al.* 2006. *Cancer Res.* 66:7317. [PubMed](#)
4. Malin D, *et al.* 2011. *Clin Cancer Res.* 17:5005. [PubMed.](#)

**Description:** DR4 is 56 kD member 10A of the TNFR superfamily (TNFRSF10A), also known as TRAIL-R1, Apo-2, and CD261. It is expressed at low levels by activated T cells and some tumors. After TRAIL engagement, DR4 (TRAIL-R1), through activation of NF- $\kappa$ B, induces apoptosis in the TRAIL ligated cell.

**Antigen References:**

1. Macfarlane M. 2003. *Toxicol. Lett.* 139:89.
2. Baetu T, *et al.* 2002. *Cytokine Growth Factor Rev.* 13:199.
3. Degli-Esposti M. 1999. *J. Leukoc. Biol.* 65:535.